US EditionDespite Regulated Access, the Consumption and Reimbursement of Anti-Obesity Drugs Is Taking Off.
11 Articles
11 Articles
Despite strictly regulated access, prescriptions for anti-obesity drugs such as Ozempic are already costing 76 million euros per year to the Social Security. And the worst would be coming, writes Lecho in his Saturday edition. ...
Until now, the initial prescription of these drugs, such as Wegovy, Mounjaro or Saxenda, had to be performed by a physician specializing in endocrinology-diabetology-nutrition.
So far, the initial prescription of Wegovy, Mounjaro and Saxenda had to be performed by a physician specialized in endocrinology-diabetology-nutrition.
As of Monday, June 23, all doctors will be allowed to prescribe GLP-1 drugs against obesity – Wegovy, Mounjaro and Saxenda – whether for
The announcement was made on Friday, 20 June by the National Medicines Agency (ANSM).
As of June 23, all doctors will be able to prescribe the anti-obesity medicines Wegovy, Mounjaro and Saxenda, announced the ANSM, which aims to facilitate access to these treatments. Up to now reserved for patients with...
Coverage Details
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
To view factuality data please Upgrade to Premium
